ReviewFrontiers in oncology2026
The role and therapeutic potential of nanotechnology-mediated ferroptosis regulation in myelodysplastic syndromes.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis and an increased risk of progression to acute myeloid leukemia (AML). Patients with MDS often develop progressive systemic iron overload due to ineffective erythropoiesis, dysregulated hepcidin expression, and repeated blood transfusions. Excess free iron promotes reactive oxygen species generation through the Fenton reaction, resulting in persistent oxidative stress within the bone marrow microenvironment. These abnormalities are closely associated with ineffective hematopoiesis. Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation. In MDS, ferroptosis appears to play a dual role. In lower-risk disease settings characterized by ineffective erythropoiesis and anemia, ferroptosis-related injury in erythroid-lineage cells may exacerbate ineffective erythropoiesis. In contrast, in higher-risk or clonally progressive disease settings, selective induction of ferroptosis in malignant clonal cells may represent a potential therapeutic strategy. However, current ferroptosis-targeting agents still face several limitations, including poor water solubility, low stability
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.